BLAC Stock Forecast 2025-2026
Distance to BLAC Price Targets
BLAC Price Momentum
🤔 Considering Bellevue Life Sciences (BLAC)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest BLAC Stock Price Targets & Analyst Predictions
BLAC has shown a year-to-date change of -73.9% and a 1-year change of -71.7%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for BLAC. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BLAC Analyst Ratings
BLAC Price Target Range
Latest BLAC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BLAC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Bellevue Life Sciences Acquisition Corp. (BLAC) Competitors
The following stocks are similar to Bellevue Life Sciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Bellevue Life Sciences Acquisition Corp. (BLAC) Financial Data
Bellevue Life Sciences Acquisition Corp. has a market capitalization of $6.98M with a P/E ratio of 540.5x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of +1.2%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Bellevue Life Sciences Acquisition Corp. (BLAC) Business Model
About Bellevue Life Sciences Acquisition Corp.
Facilitates public investment in life sciences companies.
The company operates as a special purpose acquisition company (SPAC) that raises capital through its own initial public offering to fund mergers with businesses in the life sciences sector. By targeting industries such as biotechnology, pharmaceuticals, and medical devices, it enables these companies to access public capital more efficiently than through traditional IPOs.
Bellevue Life Sciences Acquisition Corp. plays a crucial role in the financial market by providing a streamlined path for life sciences companies to secure investment, which in turn accelerates their research, development, and commercialization efforts. The leadership's expertise in public markets enhances strategic growth for the acquired companies, making it an attractive investment opportunity in the growing life sciences field.
Company Information
Sector
Financial Services
Industry
Shell Companies
Employees
0
CEO
Mr. Kuk Hyoun Hwang
Country
United States
IPO Year
2023
Website
www.bellevuespac.comBellevue Life Sciences Acquisition Corp. (BLAC) Latest News & Analysis
Bellevue Life Sciences Acquisition Corp. announced stockholder approval for its business combination with OSR Holdings Co., Ltd. at a special meeting held on February 13, 2025.
Approval of the business combination between BLAC and OSR Holdings can impact share prices and market sentiment, indicating potential growth and investment opportunities in the biotech sector.
Bellevue Life Sciences Acquisitions Corp. (Nasdaq: BLAC) adjourned its special stockholder meeting on May 10, 2024, without conducting business, and will reconvene it on May 13, 2024, at 9:00 a.m.
The adjournment of the Special Meeting without conducting business may signal uncertainty or delays in corporate decisions, potentially impacting stock performance and investor confidence.
OSR Holdings signed an MOU with SillaJen to collaborate on technology and clinical development for immuno-oncology drugs, aiming to create synergies in their platforms and drug candidates.
The MOU between OSR Holdings and SillaJen signals potential growth in immuno-oncology, which could enhance their market positions and attract investor interest in biotechnology.
Bellevue Life Sciences Acquisition Corp. (BLAC) announced a partnership with OSR Holdings Co., Ltd. on November 16, 2023. Further details on the deal were not provided.
The merger between Bellevue Life Sciences Acquisition Corp. and OSR Holdings may impact stock valuations, investor sentiment, and future growth potential in the biotech sector.
Bellevue Life Sciences Acquisition Corp. (BLAC) and OSR Holdings, Ltd. have signed a non-binding letter of intent for a business combination expected to close in Q4 2023, making OSR Holdings public.
The merger could enhance market visibility and growth potential for OSR Holdings, impacting share prices and investor interest in both companies.
Frequently Asked Questions About BLAC Stock
What is Bellevue Life Sciences Acquisition Corp.'s (BLAC) stock forecast for 2025?
Analyst forecasts for Bellevue Life Sciences Acquisition Corp. (BLAC) are not currently available. The stock is trading at $3.01.
Is BLAC stock a good investment in 2025?
Analyst ratings for BLAC are not currently available. The stock is currently trading at $3.01. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BLAC stock?
Price predictions from Wall Street analysts for BLAC are not currently available. The stock is trading at $3.01.
What is Bellevue Life Sciences Acquisition Corp.'s business model?
The company operates as a special purpose acquisition company (SPAC) that raises capital through its own initial public offering to fund mergers with businesses in the life sciences sector. By targeting industries such as biotechnology, pharmaceuticals, and medical devices, it enables these companies to access public capital more efficiently than through traditional IPOs.
What is the highest forecasted price for BLAC Bellevue Life Sciences Acquisition Corp.?
Price targets from Wall Street analysts for BLAC are not currently available. The stock is trading at $3.01.
What is the lowest forecasted price for BLAC Bellevue Life Sciences Acquisition Corp.?
Price targets from Wall Street analysts for BLAC are not currently available. The stock is trading at $3.01.
What is the overall BLAC consensus from analysts for Bellevue Life Sciences Acquisition Corp.?
Analyst ratings for BLAC are not currently available. The stock is trading at $3.01.
How accurate are BLAC stock price projections?
Stock price projections, including those for Bellevue Life Sciences Acquisition Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
